Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Trial of Cervidil (Dinoprostone, Prostaglandin E2 (PGE2), Insert) for Outpatient Pre-induction of Cervical Ripening in Women at 39.0-41.6 Weeks Gestation

NCT03806231 is registered in ClinicalTrials.gov with Intermountain Health Care, Inc. as lead sponsor.

NCT NCT03806231
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03806231 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Trial of Cervidil (Dinoprostone, Prostaglandin E2 (PGE2), Insert) for Outpatient Pre-induction of Cervical Ripening in Women at 39.0-41.6 Weeks Gestation
Lead sponsor
Intermountain Health Care, Inc.
Phase
Phase 3
Overall status
Terminated
Start date
August 7, 2019
Completion date
April 11, 2020
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

induction of labor affected fetus / newborn